Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822155 | 0.88 | MCHR1 (0.46) | HTR1BMCHR1ALDH1A1KDM4EPDE4A | |
| SCHEMBL4568915 | 0.84 | MCHR1 (0.47) | HTR1BHTR1DMCHR1 | |
| SCHEMBL2206901 | 0.83 | MCHR1 (0.49) | HTR1BMCHR1KDM4E | |
| SCHEMBL29818908 | 0.83 | MCHR1 (0.49) | HTR1BMCHR1KDM4E | |
| Ammonia Solution, Strong SCHEMBL4198347 | 0.80 | MCHR1 (0.48) | MCHR1ALDH1A1KDM4EKMT2A | |
| SCHEMBL19291642 | 0.79 | HTR1B (0.50) | HTR1BHTR1DALDH1A1KDM4ECARM1 | |
| SCHEMBL25819210 | 0.79 | HTR1B (0.50) | HTR1BHTR1DALDH1A1KDM4ECARM1 | |
| SCHEMBL18721737 | 0.79 | HTR1B (0.50) | HTR1BHTR1DALDH1A1KDM4ECARM1 | |
| SCHEMBL2209601 | 0.79 | KMT2A (0.45) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL25819240 | 0.77 | PARP10 (0.47) | HTR1BCARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | HTR1B 960/4885HTR1D 1401/4885MCHR1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.